Bizarre Patents
A fork with timer for providing a cue to a user after an elapsed period of time for indicating that another bite of food using the fork may be taken.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173128 | Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells. ... | 05/08/2012 |
| 8124086 | Antibodies that bind cell-associated CA 125/O772P and methods of use thereof The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provi... | 02/28/2012 |
| 8066996 | Anti-CCR7 receptor antibodies for the treatment of cancer Antibodies, or antigen-binding fragment thereof, which bind to a CCR7 receptor are capable of selectively killing, impairing migration and/or blocking dissemination of tumor cells expressing a CCR7 receptor. Use of said antibodies for killing or for inducing apoptos... | 11/29/2011 |
| 8062636 | Antibody therapy The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this compositi... | 11/22/2011 |
| 8038994 | Combination therapy for treating disease Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor... | 10/18/2011 |
| 8021662 | Microorganisms for therapy Methods for production of tumor-specific antibodies are provided. The methods employ microorganisms that are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tis... | 09/20/2011 |
| 8017119 | Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for perios... | 09/13/2011 |
| 8007797 | Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use The present invention relates to the use of a compound that specifically binds to JAM-C or JAM-B for the treatment of gliomas. More specifically the invention relates to the use of an antagonist of JAM-B or JAM-C for the treatment of glioma, in particular astrocytom... | 08/30/2011 |
| 7981418 | Predicting response to a HER inhibitor The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ova... | 07/19/2011 |
| 7939072 | Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising same A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, ther... | 05/10/2011 |
| 7919090 | Antibody therapy The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this compositi... | 04/05/2011 |
| 7879325 | HER2 antibody composition A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses... | 02/01/2011 |
| 7815906 | Compositions and methods for restoring sensitivity to treatment with HER2 antagonists Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition... | 10/19/2010 |
| 7811565 | Antibodies and related molecules that bind to 161P2F10B proteins Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 16... | 10/12/2010 |
| 7811564 | Prostate cancer diagnosis and treatment The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prost... | 10/12/2010 |
| 7799327 | Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment This invention describes a method whereby human autoimmune antibodies are used as carrier compounds to deliver imaging agents and pharmaceutical drugs to the tumor in the human patient. These autoantibodies have the propensity to localize in necrotic areas of tumors... | 09/21/2010 |
| 7758860 | Protein formulations with reduced viscosity and uses thereof Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the prote... | 07/20/2010 |
| 7744880 | Cell growth inhibitors containing anti-glypican 3 antibody Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient. ... | 06/29/2010 |
| 7744881 | Human DR4 antibodies and uses thereof Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided. ... | 06/29/2010 |
| 7708998 | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those d... | 05/04/2010 |
| 7691377 | Methods and compositions for treating melanoma A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereof ... | 04/06/2010 |
| 7682612 | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen. ... | 03/23/2010 |
| 7678372 | Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer The invention provides a method for the therapeutic treatment of a cancer in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 comprises at least one point mutation in the transmembr... | 03/16/2010 |
| 7560111 | HER2 antibody composition A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses... | 07/14/2009 |
| 7504103 | Methods of cancer diagnosis and therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 03/17/2009 |
| 7449184 | Fixed dosing of HER antibodies The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab. ... | 11/11/2008 |
| 7435415 | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC) The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monit... | 10/14/2008 |
| 7435412 | Chronic lymphocytic leukemia cell line The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are usefu... | 10/14/2008 |
| 7435590 | Monoclonal antibody and hybridoma producing the same The present invention establishes a simple and a highly sensitive detection method for hEPR and provides a novel detection method for human tumors which express hEPR. In particular, the present invention provides a monoclonal antibody which specifically recognizes h... | 10/14/2008 |
| 7431926 | Tumor supressor gene p33ING2 The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods ... | 10/07/2008 |
| 7429382 | Antibodies that bind cell-associated CA 125/O772P and methods of use thereof The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provi... | 09/30/2008 |
| 7427399 | Antibodies and related molecules that bind to 161P2F10B proteins Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 16... | 09/23/2008 |
| 7427400 | Methods of cancer diagnosis and therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 09/23/2008 |
| 7413736 | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The h... | 08/19/2008 |
| 7399469 | Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancrea... | 07/15/2008 |
| 7399468 | Diagnostic and therapeutic use of antibodies against the urokinase receptor The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high ... | 07/15/2008 |
| 7390486 | PRO4381 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 06/24/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7381407 | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In p... | 06/03/2008 |
| 7381411 | Aglyco products and methods of use Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B, which are immunogenic epitopes responsible for recognition of antigens by ... | 06/03/2008 |
